Cargando…

Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab

Patient: Female, 60-year-old Final Diagnosis: Amyloid light-chain amyloidosis • hepatic amyloidosis Symptoms: Abdominal pain • anemia • emesis Medication: — Clinical Procedure: Bone marrow biopsy • exploratory laparotomy • hepatectomy • stem cell transplant Specialty: Hematology • Oncology OBJECTIVE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rybinski, Brad, Kocoglu, Mehmet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404164/ https://www.ncbi.nlm.nih.gov/pubmed/34421115 http://dx.doi.org/10.12659/AJCR.933241

Ejemplares similares

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
por: Theodorakakou, Foteini, et al.
Publicado: (2021)

Hepatic Sinusoidal Obstruction Syndrome in a Patient With Multiple Myeloma Treated With CyBorD
por: Tariq, Tooba, et al.
Publicado: (2019)

A patient with POEMS syndrome responding to modified CyBorD chemotherapy as a bridge to autologous stem cell transplantation
por: Milam, Emily C., et al.
Publicado: (2019)

Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial
por: Reeder, Craig B., et al.
Publicado: (2009)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Role of Daratumumab in Cardiac AL Amyloidosis
por: Gertz, Morie A.
Publicado: (2022)

Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy
por: Chitimus, Diana Maria, et al.
Publicado: (2022)

Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
por: Suzuki, Kenshi, et al.
Publicado: (2023)

T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab‐based therapy
por: Wang, Yujia, et al.
Publicado: (2021)

Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era
por: Rybinski, Brad, et al.
Publicado: (2022)

Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report
por: Li, Xian, et al.
Publicado: (2022)

P903: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE IN NEWLY DIAGNOSED PATIENTS WITH MAYO 2004 STAGE 3 LIGHT-CHAIN AMYLOIDOSIS: A PROSPECTIVE PHASE 2 STUDY
por: Gao, Y.-J., et al.
Publicado: (2022)

Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)
por: Sammartano, Vincenzo, et al.
Publicado: (2022)

Light Chain (AL) Amyloidosis: The Journey to Diagnosis
por: McCausland, Kristen L., et al.
Publicado: (2017)

Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis
por: Sun, Chunyan, et al.
Publicado: (2022)

Light chain (AL) amyloidosis: update on diagnosis and management
por: Rosenzweig, Michael, et al.
Publicado: (2011)

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis
por: Hughes, David, et al.
Publicado: (2020)

Impact of Induction Treatment on Stem Cell Collection: A COVID Related Study
por: Rybinski, Brad, et al.
Publicado: (2021)

Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience
por: Roccatello, Dario, et al.
Publicado: (2020)

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience
por: Jeryczynski, G., et al.
Publicado: (2021)

Bör Sverige lafmna CERN?
Publicado: (1978)

Racial disparities in patients diagnosed with light chain (AL) amyloidosis
por: D’Souza, Anita, et al.
Publicado: (2021)

Light Chain (AL) Cardiac Amyloidosis: A Diagnostic Dilemma
por: Abdelazeem, Basel, et al.
Publicado: (2021)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Differences in Immunoglobulin Light Chain Species Found in Urinary Exosomes in Light Chain Amyloidosis (AL)
por: Ramirez-Alvarado, Marina, et al.
Publicado: (2012)

Significant role of magnetic resonance imaging for the diagnosis and evaluation of cardiac amyloidosis in primary light chain amyloidosis
por: Sekiguchi, Yasunobu, et al.
Publicado: (2020)

Pseudo-Kappa Light Chain Restricted Hematogones in Patients Receiving Daratumumab
por: Tariq, Hamza, et al.
Publicado: (2022)

BOR beam control rack layout
por: Schneider, G C
Publicado: (1993)

A generalization of a theorem of Bor
por: Özarslan, Hikmet Seyhan, et al.
Publicado: (2017)

Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis
por: Morgan, Gareth J., et al.
Publicado: (2021)

Geroi bor'by za osvobozhdenie Latinskoj Ameriki
por: Prieto, Alberto, 1939-
Publicado: (1985)

Borna [bor′nә] disease virus
Publicado: (2009)

Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis
por: Wechalekar, A D, et al.
Publicado: (2017)

PB1989: LIGHT CHAIN AMYLOIDOSIS (AL): THE EXPERIENCE OF A TUNISIAN CENTER
por: Kallel, F., et al.
Publicado: (2022)

Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
por: Jensen, Christopher E., et al.
Publicado: (2022)

P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, E., et al.
Publicado: (2022)

Mutations in Specific Structural Regions of Immunoglobulin Light Chains Are Associated with Free Light Chain Levels in Patients with AL Amyloidosis
por: Poshusta, Tanya L., et al.
Publicado: (2009)

Novel Therapies in Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

Splenic rupture secondary to amyloid light-chain (AL) amyloidosis associated with multiple myeloma
por: Buzalewski, Jarrod, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7kl44ib51k51bkkfehcpj5vkha